(Q39984210)

16 September 2017

The effect of dapagliflozin on renal function in patients with type 2 diabetes (English)

1 reference

16 September 2017

0 references

0 references

Donald Elliott Kohan

1

1 reference

16 September 2017

Paola Fioretto

2

1 reference

16 September 2017

Kristina Johnsson

3

1 reference

16 September 2017

Shamik Parikh

4

1 reference

16 September 2017

Agata Ptaszynska

5

1 reference

16 September 2017

Lisa Ying

6

1 reference

16 September 2017

language of work or name

1 reference

19 February 2016

1 reference

16 September 2017

Journal of Nephrology

1 reference

16 September 2017

29

1 reference

16 September 2017

3

1 reference

16 September 2017

391-400

1 reference

https://scigraph.springernature.com/pub.10.1007/s40620-016-0261-1

16 September 2017

0 references

cites work

Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins.

1 reference

https://api.crossref.org/works/10.1007%2FS40620-016-0261-1

The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-016-0261-1

Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-016-0261-1

Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-016-0261-1

Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-016-0261-1

Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-016-0261-1

Glucose handling by the kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-016-0261-1

SGLT2 mediates glucose reabsorption in the early proximal tubule.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-016-0261-1

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-016-0261-1

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-016-0261-1

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-016-0261-1

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-016-0261-1

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-016-0261-1

Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-016-0261-1

A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-016-0261-1

Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-016-0261-1

Current and emerging antiglycaemic pharmacological therapies: the renal perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-016-0261-1

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-016-0261-1

Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-016-0261-1

Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-016-0261-1

Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-016-0261-1

Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-016-0261-1

Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-016-0261-1

Assessing kidney function--measured and estimated glomerular filtration rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-016-0261-1

Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-016-0261-1

Association between serum uric acid and development of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-016-0261-1

The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-016-0261-1

SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-016-0261-1

Serum uric acid is associated with microalbuminuria and subclinical atherosclerosis in men with type 2 diabetes mellitus

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26894924

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26894924

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26894924

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S40620-016-0261-1

1 reference

16 September 2017

1 reference